The company intends to channel the gross proceeds into its "dabogratinib 3x3" development strategy. This initiative focuses on low-grade upper tract urothelial carcinoma, intermediate-risk non-muscle invasive bladder cancer, and achondroplasia. Remaining funds will support ongoing preclinical drug discovery programs and general corporate operations.
Tyra Biosciences Prices $400 Million Public Offering
Carlsbad-based Tyra Biosciences has priced a $400 million underwritten offering, issuing 9.08 million shares of common stock at $22.03 per share. The biotech firm is also offering pre-funded warrants to specific investors, with the entire transaction expected to close on September 15, 2026, subject to standard closing conditions.
RA Capital Management led the investment round, drawing interest from a broad group of institutional players including Invus, Commodore Capital, BVF Partners, and Janus Henderson Investors. A syndicate of major financial institutions, led by Jefferies, Guggenheim Securities, Cantor, Barclays, and William Blair, is managing the offering under a shelf registration statement filed with the Securities and Exchange Commission.
Comments (0)
No comments yet. Be the first!